Skip to main content
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1990 Jan;32(1):22–28. doi: 10.1007/BF01741720

Induction of antitumor activity in macrophages by mycoplasmas in concert with interferon

Kazuko Uno 1,2, Morio Takema 1,3, Shigetaka Hidaka 4, Reishi Tanaka 4, Takao Konishi 3,4, Takuma Kato 1, Shinji Nakamura 1, Shigeru Muramatsu 1,
PMCID: PMC11038328  PMID: 2126981

Abstract

The in vitro growth of tumor cells infected with mycoplasmas was suppressed by macrophages pretreated with interferon (IFN), but the growth of mycoplasma-free tumor cells was not suppressed. Pretreatment of macrophages with IFN plus mycoplasmas or their soluble factors either simultaneously or sequentially, IFN first and mycoplasmas second, but not in the reverse order, was effective in activating macrophages to suppress the growth of mycoplasma-free tumor cells. Macrophages from C3H/HeJ mice (which respond only slightly to lipopolysaccharide) were activated by IFN plus mycoplasmas or their soluble factor, and their action was not influenced by the addition of a lipopolysaccharide-neutralizing agent, polymyxin B. These results suggest that the macrophage-activating agent in mycoplasmas does not mimic lipopolysaccharide. The administration of mycoplasmas plus IFN to mice with ascitic or solid tumors resulted in the reduction of tumor growth. The survival rate of tumor-bearing mice was improved by the administration of mycoplasmas, and this was synergistically enhanced by the addition of IFN. These results indicate (a) that mycoplasmas can be useful as a biological response modifier, and (b) that care should be taken to prevent contamination with mycoplasmas in experiments on macrophage activation.

Keywords: Tumor Cell, Survival Rate, Tumor Growth, Cancer Research, Interferon

References

  • 1.Dean RT, Virelizer JL. Interferons as a macrophage activating factor. I. Enhancement of cytotoxicity by fresh and matured human monocytes in the absence of other soluble signals. Clin Exp Immunol. 1983;5:501. [PMC free article] [PubMed] [Google Scholar]
  • 2.Dietz JN, Cole BC. Direct activation of the J774.1 murine macrophage cell line byMycoplasma arthritidis . Infect Immun. 1982;37:811. doi: 10.1128/iai.37.2.811-819.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Fujiwara H, Takai Y, Sakamoto K, Hamaoka T. The mechanism of tumor growth inhibition by tumor-specific Lyt 1+2− T-cells: I. Antitumor effect of Lyt 1+2− T-cells depends on the existence of adherent cells. J Immunol. 1985;135:2187. [PubMed] [Google Scholar]
  • 4.Fulton AM. Macrophage and cancer. Boca Raton, Florida: CRC Press; 1988. Tumor-associated macrophages; p. 97. [Google Scholar]
  • 5.Gallily R, Sher T, Ben-av P, Loewenstein J. Tumor necrosis factor as a mediator ofMycoplasma orale-induced cell lysis by macrophages. Cell Immunol. 1989;121:146. doi: 10.1016/0008-8749(89)90012-9. [DOI] [PubMed] [Google Scholar]
  • 6.Hamilton TA, Adams DO. Molecular mechanisms of signal transduction in macrophages. Immunol Today. 1987;8:151. doi: 10.1016/0167-5699(87)90145-9. [DOI] [PubMed] [Google Scholar]
  • 7.Loewenstein J, Rottem S, Gallily R. Induction of macrophagemediated cytolysis of neoplastic cells by mycoplasmas. Cell Immunol. 1983;77:290. doi: 10.1016/0008-8749(83)90029-1. [DOI] [PubMed] [Google Scholar]
  • 8.Pace JL, Russell SW, Leblanc PA, Murasko DM. Comparative effects of various classes of mouse interferons on macrophage activation for tumor cell killing. J Immunol. 1985;134:977. [PubMed] [Google Scholar]
  • 9.Ruco LP, Meltzer MS. Defective tumoricidal capacity of macrophages from C3H/HeJ mice. J Immunol. 1978;120:329. [PubMed] [Google Scholar]
  • 10.Russell WC, Newman C, Williamson DH. A simple cytochemical technique for demonstration of DNA in cells infected with mycoplasmas and viruses. Nature. 1975;253:461. doi: 10.1038/253461a0. [DOI] [PubMed] [Google Scholar]
  • 11.Schultz RM, Papamatheakis JD, Chirigos MA. Interferon: an inducer of macrophage activation by polyanions. Science. 1977;197:674. doi: 10.1126/science.877584. [DOI] [PubMed] [Google Scholar]
  • 12.Schultz RM, Chirigos MA, Heine UI. Functional and morphologic characteristics of interferon-treated macrophages. Cell Immunol. 1978;35:84. doi: 10.1016/0008-8749(78)90128-4. [DOI] [PubMed] [Google Scholar]
  • 13.Sinigaglia F, Talmadge KW. Inhibition of3H-thymidine incorporation byMycoplasma arginini-infected cells due to enzymatic cleavage of the nucleoside. Eur J Immunol. 1985;15:692. doi: 10.1002/eji.1830150710. [DOI] [PubMed] [Google Scholar]
  • 14.Uno K, Shimizu S, Ido M, Inaba K, Oku T, Kishida T, Muramatsu S. Direct and indirect effects of interferon on in vivo murine tumor cell growth. Cancer Res. 1985;45:1320. [PubMed] [Google Scholar]
  • 15.Uno K, Shimizu S, Inaba K, Kitaura M, Nakahira K, Kato T, Yamaguchi Y, Muramatsu S. Effect of recombinant human interferon-αA/D on in vivo murine tumor cell growth. Cancer Res. 1988;48:2366. [PubMed] [Google Scholar]
  • 16.Warfel AH. Factors affecting the in vitro activation of resident peritoneal macrophages by mouse interferon. J Interferon Res. 1983;3:271. [Google Scholar]
  • 17.White GRM, Ockey CH. SCE induction and harlequin staining in mycoplasma-contaminated Chinese hamster cells. Chromosoma. 1985;93:165. doi: 10.1007/BF00293164. [DOI] [PubMed] [Google Scholar]
  • 18.Yamaguchi Y, Inaba K, Kawai J, Kato T, Nakamura S, Uno K, Muramatsu S. Tumor-specific T cells which form clusters with dendritic cells and tumor cells and deliver macrophage-activating factors. Jpn J Cancer Res. 1989;80:141. doi: 10.1111/j.1349-7006.1989.tb02282.x. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES